A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer

Trial Profile

A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs BPX 601 (Primary) ; Rimiducid
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 21 Feb 2017 According to Bellicum Pharmaceuticals media release, first patient has been dosed in this trial.
    • 04 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 13 Oct 2016 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top